Skip to main content
. 2019 Dec 26;2(1):vdz058. doi: 10.1093/noajnl/vdz058

Figure 2.

Figure 2.

The combination of celecoxib plus anti-PD-1 antibody synergistically improves survival rates in a murine malignant glioma model. (A) Experimental protocol; an anti-PD-1 antibody was intraperitoneally (i.p.) injected at 20 mg/kg on days 0 and 10 mg/kg every 6 days until day 30 following the injection of murine glioma stem cells (GSCs). Celecoxib was i.p. injected at 10 mg/kg, every day for 30 days. (B) Tumor volumes in mice sacrificed on day 14 (mean ± SD, n = 5). *P < .05, **P <.01 vs. vehicle control (VC), ANOVA followed by the Dunnett test. (C) Kaplan–Meier survival curves (each experiment was repeated two times, 12 mice/group). **P < .01 in relation to the other groups based on a Mantel-Cox test. (D) Expression of PD-L1 protein as measured by western blotting. Each experiment was repeated three times (mean ± SD). *P < .05 vs. VC based on a Student’s t-test.